Publication Type:Journal Article
Source:Biomed Data J, Volume 1, Issue 1, p.39-41 (2015)
A data journal in the biomedical field is an innovative and interesting task with potential benefits to the scientific society, the pharmaceutical and biotechnology industrials, as well as the medical institutions and authorities. It can serve as a source to stimulate, using computational modeling and bioinformatics, the bridging of biomedicine and basic biology researches and connecting of pharmaceutical and biotechnology industrials with academy. In the era of various high throughput technologies and big data, it could become a powerful driving force to combine expertise to understand the complexity of life and to catalyze new innovative therapeutics and diagnosis.
The developments of various high-throughput and/or high-content drug-screening techniques are aiming not only to probe a large number of chemical compounds, but also to obtain deep insights into the molecule/molecule interaction associated with the diversity of chemical space, the structure-activity relationship, as well as the pharmacological mechanism. Moreover, the cell-based drug-screening approaches can also shed new light on the dynamics and regulation of proteins and genes associated with various physiological and pathological states.
To reflect on these developments, the BMDJ Editorial Board announed a Call for Papers for a special issue on datasets in the field of drug screening and discovery: http://biomed-data.eu/calls-for-papers/high-throughput-drug-screening